Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024)

Century Therapeutics (IPSC) has 3 years of Non-Current Deffered Revenue data on file, last reported at $109.8 million in Q3 2024.

• On a quarterly basis, Non-Current Deffered Revenue fell 2.12% year-over-year to $109.8 million in Q3 2024; TTM through Sep 2024 was $109.8 million, a 2.12% decrease from a year earlier, with the FY2023 full-year figure at $111.4 million, changed 0.49% from the prior year.
• Non-Current Deffered Revenue for Q3 2024 stood at $109.8 million, roughly flat from $109.8 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for IPSC reached as high as $115.8 million in Q1 2022 and fell as low as $109.2 million in Q2 2023.
• Historically, Non-Current Deffered Revenue has averaged $111.2 million across 3 years, with a median of $110.8 million in 2022.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 1.09% in 2023 and fell as far as 5.17% in 2023.
• Year by year, Non-Current Deffered Revenue stood at $110.8 million in 2022, then advanced by 0.49% to $111.4 million in 2023, then fell by 1.45% to $109.8 million in 2024.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $109.8 million in Q3 2024, $109.8 million in Q2 2024, and $110.3 million in Q1 2024.